Inhibition of platelet aggregation by 1-methyl-4-phenyl pyridinium ion (MPP+) through ATP depletion: Evidence for the reduced platelet activities in Parkinson's disease
- 1 January 2009
- journal article
- research article
- Published by Taylor & Francis in Platelets
- Vol. 20 (3) , 163-170
Abstract
Neuronal accumulation of 1-methyl-4-phenylpyridinium ion (MPP+), the metabolite of neural toxin, 1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine (MPTP), induces a rapid depletion of cellular ATP level and loss of neuronal cell viability which simulates human Parkinson's disease (PD). Since ATP plays an important role in the physiology and function of platelets, which share many biochemical and physiological features with neuronal cells, we examined the effect of MPP+ on platelet aggregation and viability using freshly isolated rat platelets. While the treatment of MPP+ to platelets did not induce cytotoxicity, it significantly attenuated agonist-induced platelet aggregation in a concentration dependent manner. The inhibition of aggregation by MPP+ was mediated by the depletion of the cytoplasmic ATP pool and resultant decreased ATP secretion. Different from the previous reports in neuronal cells, MPP+ did not affect intracellular levels of glutathione and cytoplasmic Ca2+ in platelets. The combined treatment with MPP+ and 2-deoxyglucose, a glycolysis inhibitor, showed the additive effect in the decrease of ATP secretion and intracellular content. Consistent with these findings, inhibitory effects of MPP+ on platelet aggregation was significantly enhanced by the treatment with 2-deoxyglucose. In conclusion, these results suggested that MPP+ can induce ATP depletion in platelets and attenuate platelet aggregation providing a new theory on the reduced platelet activities in PD patients.Keywords
This publication has 33 references indexed in Scilit:
- Mitochondrial complex I inhibition is not required for dopaminergic neuron death induced by rotenone, MPP + , or paraquatProceedings of the National Academy of Sciences, 2008
- Complex I deficiency in Parkinson's disease frontal cortexBrain Research, 2008
- Primary and secondary agonists can use P2X1 receptors as a major pathway to increase intracellular Ca2+ in the human plateletJournal of Thrombosis and Haemostasis, 2007
- In vitro and in vivo neuroprotection by γ-glutamylcysteine ethyl ester against MPTP: Relevance to the role of glutathione in Parkinson's diseaseNeuroscience Letters, 2006
- Divergent role of calcium on Aβ- and MPTP-induced cell death in SK-N-SH neuroblastomaLife Sciences, 2006
- 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) affects the actin cytoskeleton and calcium level of Swiss 3T3 mouse fibroblastsToxicology, 1994
- Platelet aggregation in patients with Parkinson's disease.Stroke, 1991
- Properties of 3H-MPTP binding sites in human blood plateletsLife Sciences, 1986
- Ca2+‐independent secretion is dependent on cytoplasmic ATP in human plateletsFEBS Letters, 1985
- Arteriosclerosis, heredity, and some previous infections in the etiology of parkinson's disease. A case-control studyClinical Neurology and Neurosurgery, 1976